Alector Crecimiento futuro

Future controles de criterios 0/6

Se prevé que los ingresos y los beneficios de Alector disminuyan a un ritmo anual de 34.5% y 0.9% respectivamente. Se espera que el BPA crezca en un 5% al año. Se prevé que la rentabilidad financiera sea de -336.4% en 3 años.

Información clave

-0.9%

Tasa de crecimiento de los beneficios

4.96%

Tasa de crecimiento del BPA

Crecimiento de los beneficios de Biotechs	23.9%
Tasa de crecimiento de los ingresos	-34.5%
Rentabilidad financiera futura	-336.36%
Cobertura de analistas	Good
Última actualización	19 Dec 2025

Actualizaciones recientes sobre el crecimiento futuro

US$5.26 - That's What Analysts Think Alector, Inc. (NASDAQ:ALEC) Is Worth After These Results

May 11

Recent updates

Alector Stock Down After Latozinemab Failure, Eyes On Phase 2 Catalyst

Dec 16

Alector, Inc.'s (NASDAQ:ALEC) Shares Bounce 32% But Its Business Still Trails The Industry

Sep 16

This Just In: Analysts Are Boosting Their Alector, Inc. (NASDAQ:ALEC) Outlook for This Year

Aug 13

Alector, Inc.'s (NASDAQ:ALEC) Shares Bounce 29% But Its Business Still Trails The Industry

Jul 24

US$5.26 - That's What Analysts Think Alector, Inc. (NASDAQ:ALEC) Is Worth After These Results

May 11

Alector, Inc. (NASDAQ:ALEC) Stock Catapults 27% Though Its Price And Business Still Lag The Industry

May 05

ABC Platform And Latozinemab Trial Will Yield Mixed Prospects

Apr 03 Alector's ABC platform and late-stage trials, like those for latozinemab, could significantly boost revenue if successful, addressing unmet medical needs.

Alector, Inc. (NASDAQ:ALEC) Not Doing Enough For Some Investors As Its Shares Slump 26%

Mar 21

Alector: Q4 Of 2025 FTD-GRN Treatment Data Is Important Inflection Point

Mar 13

Earnings Update: Alector, Inc. (NASDAQ:ALEC) Just Reported And Analysts Are Trimming Their Forecasts

Mar 01

The Market Doesn't Like What It Sees From Alector, Inc.'s (NASDAQ:ALEC) Revenues Yet As Shares Tumble 53%

Dec 23

Need To Know: Analysts Just Made A Substantial Cut To Their Alector, Inc. (NASDAQ:ALEC) Estimates

Nov 28

Alector, Inc. (NASDAQ:ALEC) First-Quarter Results: Here's What Analysts Are Forecasting For This Year

May 11

Analysts Are Updating Their Alector, Inc. (NASDAQ:ALEC) Estimates After Its Full-Year Results

Mar 01

The Market Doesn't Like What It Sees From Alector, Inc.'s (NASDAQ:ALEC) Revenues Yet As Shares Tumble 27%

Jan 19

Alector: Good Data, Huge Cash, No Near Term Catalyst

Jan 16

Previsiones de crecimiento de beneficios e ingresos

NasdaqGS:ALEC - Estimaciones futuras de los analistas y datos financieros pasados (USD Millions)
Fecha	Ingresos	Beneficios	Flujo de caja libre	Flujo de caja operativo	Núm. de analistas medio
12/31/2027	5	-142	-121	N/A	5
12/31/2026	55	-111	-152	N/A	8
12/31/2025	17	-146	-95	N/A	8
9/30/2025	69	-108	-198	-197	N/A
6/30/2025	81	-115	-216	-216	N/A
3/31/2025	88	-123	-230	-229	N/A
12/31/2024	101	-119	-231	-230	N/A
9/30/2024	62	-158	-222	-221	N/A
6/30/2024	55	-161	-218	-217	N/A
3/31/2024	96	-121	-199	-197	N/A
12/31/2023	97	-130	-187	-184	N/A
9/30/2023	96	-141	-190	-187	N/A
6/30/2023	102	-143	-194	-190	N/A
3/31/2023	126	-135	-208	-204	N/A
12/31/2022	134	-133	-24	-20	N/A
9/30/2022	133	-136	-25	-21	N/A
6/30/2022	301	36	471	473	N/A
3/31/2022	227	-29	483	486	N/A
12/31/2021	207	-36	295	299	N/A
9/30/2021	198	-33	297	300	N/A
6/30/2021	21	-212	-189	-186	N/A
3/31/2021	18	-202	-190	-187	N/A
12/31/2020	21	-190	-172	-167	N/A
9/30/2020	22	-169	-154	-148	N/A
6/30/2020	19	-148	-144	-136	N/A
3/31/2020	23	-127	-125	-108	N/A
12/31/2019	21	-105	-115	-99	N/A
9/30/2019	24	-92	-102	-88	N/A
6/30/2019	28	-76	N/A	-82	N/A
3/31/2019	28	-62	N/A	-81	N/A
12/31/2018	28	-52	N/A	127	N/A
9/30/2018	22	-45	N/A	143	N/A
6/30/2018	15	-39	N/A	159	N/A
3/31/2018	8	-35	N/A	171	N/A
12/31/2017	4	-32	N/A	-18	N/A
12/31/2016	0	-15	N/A	-13	N/A

Previsiones de crecimiento futuro de los analistas

Ingresos vs. Tasa de ahorro: Se prevé que ALEC siga sin ser rentable en los próximos 3 años.

Beneficios vs. Mercado: Se prevé que ALEC siga sin ser rentable en los próximos 3 años.

Beneficios de alto crecimiento: Se prevé que ALEC siga sin ser rentable en los próximos 3 años.

Ingresos vs. Mercado: Se prevé que los ingresos de ALEC disminuyan en los próximos 3 años (-34.5% al año).

Ingresos de alto crecimiento: Se prevé que los ingresos de ALEC disminuyan en los próximos 3 años (-34.5% al año).

Previsiones de crecimiento de los beneficios por acción

Rentabilidad financiera futura

ROE futura: ALEC se prevé que no sea rentable en 3 años.

Descubre empresas en crecimiento

Análisis de la empresa y estado de los datos financieros

Datos	Última actualización (huso horario UTC)
Análisis de la empresa	2025/12/24 01:26
Precio de las acciones al final del día	2025/12/24 00:00
Beneficios	2025/09/30
Ingresos anuales	2024/12/31

Fuentes de datos

Los datos utilizados en nuestro análisis de empresas proceden de S&P Global Market Intelligence LLC. Los siguientes datos se utilizan en nuestro modelo de análisis para generar este informe. Los datos están normalizados, lo que puede introducir un retraso desde que la fuente está disponible.

Paquete	Datos	Marco temporal	Ejemplo Fuente EE.UU. ^*
Finanzas de la empresa	10 años	Cuenta de resultados Estado de tesorería Balance	Formulario SEC 10-K Formulario SEC 10-Q
Estimaciones del consenso de analistas	+3 años	Previsiones financieras Objetivos de precios de los analistas	Informes de análisis Blue Matrix
Precios de mercado	30 años	Precios de las acciones Dividendos, escisiones y acciones	Datos de mercado ICE Formulario S-1 de la SEC
Propiedad	10 años	Accionistas principales Información privilegiada	Formulario SEC 4 Formulario SEC 13D
Gestión	10 años	Equipo directivo Consejo de Administración	Formulario SEC 10-K Formulario SEC DEF 14A
Principales avances	10 años	Anuncios de empresas	Formulario SEC 8-K

^* Ejemplo para valores de EE.UU., para no EE.UU. se utilizan formularios y fuentes normativas equivalentes.

A menos que se especifique lo contrario, todos los datos financieros se basan en un periodo anual, pero se actualizan trimestralmente. Esto se conoce como datos de los últimos doce meses (TTM) o de los últimos doce meses (LTM). Más información.

Modelo de análisis y copo de nieve

Los detalles del modelo de análisis utilizado para generar este informe están disponibles en nuestra página de Github, también tenemos guías sobre cómo utilizar nuestros informes y tutoriales en Youtube.

Conozca al equipo de talla mundial que diseñó y construyó el modelo de análisis Simply Wall St.

Métricas industriales y sectoriales

Simply Wall St calcula cada 6 horas nuestras métricas sectoriales y de sección. Los detalles de nuestro proceso están disponibles en Github.

Fuentes analistas

Alector, Inc. está cubierta por 15 analistas. 8 de esos analistas presentaron las estimaciones de ingresos o ganancias utilizadas como datos para nuestro informe. Las estimaciones de los analistas se actualizan a lo largo del día.

Analista	Institución
Alec Stranahan	BofA Global Research
Thomas Shrader	BTIG
Pete Stavropoulos	Cantor Fitzgerald & Co.

Alector Crecimiento futuro

Future controles de criterios 0/6

Información clave

Actualizaciones recientes sobre el crecimiento futuro

Alector, Inc. Reaffirms Revenue Guidance for the Year 2025

Price target decreased by 19% to US$3.83

Price target increased by 20% to US$5.71

Alector, Inc. Updates Revenue Guidance for the Year Ending 2025

Consensus revenue estimates decrease by 14%, EPS upgraded

US$5.26 - That's What Analysts Think Alector, Inc. (NASDAQ:ALEC) Is Worth After These Results

Recent updates

Alector Stock Down After Latozinemab Failure, Eyes On Phase 2 Catalyst

Alector, Inc. Appoints Neil Berkley as Chief Financial Officer, Effective December 10, 2025

Alector, Inc. Reaffirms Revenue Guidance for the Year 2025

Alector Announces Latozinemab, Failed to Meet the Criteria for Safety and Efficacy in A Phase 3 Clinical Trial

Alector, Inc. Commits to a Plan to Reduce Workforce by Approximately 49%

Alector, Inc. to Host Virtual Research and Development Event Highlighting PGRN Franchise and Brain Carrier Programs

Alector, Inc.'s (NASDAQ:ALEC) Shares Bounce 32% But Its Business Still Trails The Industry

Co-Founder recently sold US$129k worth of stock

Price target decreased by 19% to US$3.83

Co-Founder notifies of intention to sell stock

This Just In: Analysts Are Boosting Their Alector, Inc. (NASDAQ:ALEC) Outlook for This Year

Second quarter 2025 earnings: EPS and revenues exceed analyst expectations

Price target increased by 20% to US$5.71

Alector, Inc. Updates Revenue Guidance for the Year Ending 2025

Alector, Inc. to Report Q2, 2025 Results on Aug 07, 2025

Alector, Inc.'s (NASDAQ:ALEC) Shares Bounce 29% But Its Business Still Trails The Industry

Insufficient new directors

Alector, Inc. Announces Chief Financial Officer Changes

Co-Founder recently sold US$70k worth of stock

Co-Founder notifies of intention to sell stock

Consensus revenue estimates decrease by 14%, EPS upgraded

US$5.26 - That's What Analysts Think Alector, Inc. (NASDAQ:ALEC) Is Worth After These Results

First quarter 2025 earnings: EPS exceeds analyst expectations while revenues lag behind

Alector, Inc. (NASDAQ:ALEC) Stock Catapults 27% Though Its Price And Business Still Lag The Industry

Alector, Inc., Annual General Meeting, Jun 11, 2025

New minor risk - Share price stability

Alector Announces Completion of Enrollment in the PROGRESS-AD Phase 2 Clinical Trial of AL101/GSK4527226 in Individuals with Early Alzheimer’s Disease

New minor risk - Market cap size

ABC Platform And Latozinemab Trial Will Yield Mixed Prospects

Alector Provides Executive Leadership Update

Alector, Inc. (NASDAQ:ALEC) Not Doing Enough For Some Investors As Its Shares Slump 26%

Alector: Q4 Of 2025 FTD-GRN Treatment Data Is Important Inflection Point

Co-Founder recently sold US$59k worth of stock

Price target decreased by 7.9% to US$4.22

Consensus revenue estimates fall by 67%

Co-Founder notifies of intention to sell stock

Earnings Update: Alector, Inc. (NASDAQ:ALEC) Just Reported And Analysts Are Trimming Their Forecasts

Full year 2024 earnings: EPS and revenues exceed analyst expectations

Alector, Inc. Provides Revenue Guidance for the Year Ending 2025

Insufficient new directors

The Market Doesn't Like What It Sees From Alector, Inc.'s (NASDAQ:ALEC) Revenues Yet As Shares Tumble 53%

Price target decreased by 22% to US$6.33

Co-Founder recently sold US$131k worth of stock

Co-Founder notifies of intention to sell stock

Need To Know: Analysts Just Made A Substantial Cut To Their Alector, Inc. (NASDAQ:ALEC) Estimates

Alector: Bleak Prospects After Alzheimer's Failure

Price target decreased by 37% to US$10.28

Alector, Inc. Announces Results from AL002 INVOKE-2 Phase 2 Trial in Individuals with Early Alzheimer’S Disease and Provides Business Update

Alector, Inc. announced that it expects to receive $50 million in funding from Hercules Capital, Inc., and other investors

Third quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

Alector, Inc.'s (NASDAQ:ALEC) Business And Shares Still Trailing The Industry

We Think Alector (NASDAQ:ALEC) Needs To Drive Business Growth Carefully

New minor risk - Share price stability

Alector, Inc. Presents Baseline Characteristics for Pivotal INFRONT-3 Phase 3 Clinical Trial at the 14th International Conference on Frontotemporal Dementias (ISFTD 2024)

Co-Founder recently sold US$129k worth of stock

Co-Founder recently sold US$129k worth of stock

Board Member recently sold US$228k worth of stock

Second quarter 2024 earnings: EPS and revenues exceed analyst expectations

Alector, Inc. to Report Q2, 2024 Results on Aug 07, 2024

Alector Presents Baseline Characteristics for INVOKE-2 Phase 2 Clinical Trial of AL002 at the Alzheimer's Association International Conference® 2024 (AAIC®)

Alector, Inc.'s (NASDAQ:ALEC) Price Is Right But Growth Is Lacking

Co-Founder recently sold US$121k worth of stock

Co-Founder notifies of intention to sell stock

Alector, Inc. (NASDAQ:ALEC) First-Quarter Results: Here's What Analysts Are Forecasting For This Year

Alector, Inc. Reiterates Revenue Guidance for the Year Ending 2024

First quarter 2024 earnings released: US$0.39 loss per share (vs US$0.55 loss in 1Q 2023)

Alector, Inc., Annual General Meeting, Jun 12, 2024

Co-Founder recently sold US$130k worth of stock

Consensus revenue estimates decrease by 37%, EPS upgraded